IRIS Accounts Production v26.1.10.61 10741984 director 1.5.25 30.4.26 30.4.26 false true false false true false Ordinary A 1.00000 Ordinary B 1.00000 Ordinary C 1.00000 Ordinary D 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 10741984 2025-04-30 10741984 2026-04-30 10741984 2025-05-01 2026-04-30 10741984 2024-04-30 10741984 2024-05-01 2025-04-30 10741984 2025-04-30 10741984 ns15:EnglandWales 2025-05-01 2026-04-30 10741984 ns14:PoundSterling 2025-05-01 2026-04-30 10741984 ns10:Director1 2025-05-01 2026-04-30 10741984 ns10:PrivateLimitedCompanyLtd 2025-05-01 2026-04-30 10741984 ns10:SmallEntities 2025-05-01 2026-04-30 10741984 ns10:AuditExempt-NoAccountantsReport 2025-05-01 2026-04-30 10741984 ns10:SmallCompaniesRegimeForDirectorsReport 2025-05-01 2026-04-30 10741984 ns10:SmallCompaniesRegimeForAccounts 2025-05-01 2026-04-30 10741984 ns10:FullAccounts 2025-05-01 2026-04-30 10741984 ns10:OrdinaryShareClass1 2025-05-01 2026-04-30 10741984 ns10:OrdinaryShareClass2 2025-05-01 2026-04-30 10741984 ns10:OrdinaryShareClass3 2025-05-01 2026-04-30 10741984 ns10:OrdinaryShareClass4 2025-05-01 2026-04-30 10741984 ns5:CurrentFinancialInstruments 2026-04-30 10741984 ns5:CurrentFinancialInstruments 2025-04-30 10741984 ns5:ShareCapital 2026-04-30 10741984 ns5:ShareCapital 2025-04-30 10741984 ns5:RetainedEarningsAccumulatedLosses 2026-04-30 10741984 ns5:RetainedEarningsAccumulatedLosses 2025-04-30 10741984 ns10:RegisteredOffice 2025-05-01 2026-04-30 10741984 ns5:FurnitureFittings 2025-04-30 10741984 ns5:FurnitureFittings 2025-05-01 2026-04-30 10741984 ns5:FurnitureFittings 2026-04-30 10741984 ns5:FurnitureFittings 2025-04-30 10741984 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2026-04-30 10741984 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-04-30 10741984 ns10:OrdinaryShareClass1 2026-04-30 10741984 ns10:OrdinaryShareClass2 2026-04-30 10741984 ns10:OrdinaryShareClass3 2026-04-30 10741984 ns10:OrdinaryShareClass4 2026-04-30 10741984 ns10:Director1 1 2025-04-30 10741984 ns10:Director1 1 2024-04-30 10741984 ns10:Director1 1 2025-05-01 2026-04-30 10741984 ns10:Director1 1 2024-05-01 2025-04-30 10741984 ns10:Director1 1 2026-04-30 10741984 ns10:Director1 1 2025-04-30

REGISTERED NUMBER: 10741984 (England and Wales)

Unaudited Financial Statements for the Year Ended 30th April 2026

for

Bespoke Narcosis Limited

Bespoke Narcosis Limited (Registered number: 10741984)

Contents of the Financial Statements

for the Year Ended 30th April 2026

Page |

Balance Sheet | 1 |

Notes to the Financial Statements | 2 |

Bespoke Narcosis Limited (Registered number: 10741984)

Balance Sheet

30th April 2026

| 30.4.26 | 30.4.25 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 911 |  | 1,314 |  |

CURRENT ASSETS

Debtors | 5 | 7,471 |  | 1,815 |  |

Cash at bank | 9,340 |  | 11,232 |  |

16,811 |  | 13,047 |  |

CREDITORS

Amounts falling due within one year | 6 | 16,632 |  | 17,926 |  |

NET CURRENT ASSETS/(LIABILITIES) | 179 |  | (4,879 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | 1,090 |  | (3,565 | ) |

PROVISIONS FOR LIABILITIES | 173 |  | 184 |  |

NET ASSETS/(LIABILITIES) | 917 |  | (3,749 | ) |

CAPITAL AND RESERVES

Called up share capital | 7 | 109 |  | 106 |  |

Retained earnings | 808 |  | (3,855 | ) |

SHAREHOLDERS' FUNDS | 917 |  | (3,749 | ) |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th April 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th April 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 21st July 2026 and were signed by:

Dr D R Nethercott - Director

Bespoke Narcosis Limited (Registered number: 10741984)

Notes to the Financial Statements

for the Year Ended 30th April 2026

1. | COMPANY INFORMATION

| Bespoke Narcosis Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

| Registered number: | 10741984

| Registered office: | The Lexicon

| Mount Street

| Manchester

| M2 5NT

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Revenue from the provision of professional services is recognised on delivery of the service.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Tangible Fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment loss.

| Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

| Fixtures and Fittings - 25% on cost

| The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Bespoke Narcosis Limited (Registered number: 10741984)

Notes to the Financial Statements - continued

for the Year Ended 30th April 2026

2. | ACCOUNTING POLICIES - continued

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2025 - 1 ) .

4. | TANGIBLE FIXED ASSETS

| Fixtures

| and

| fittings

£ |

| COST

| At 1st May 2025 | 6,971 |  |

| Additions | 454 |  |

| At 30th April 2026 | 7,425 |  |

| DEPRECIATION

| At 1st May 2025 | 5,657 |  |

| Charge for year | 857 |  |

| At 30th April 2026 | 6,514 |  |

| NET BOOK VALUE

| At 30th April 2026 | 911 |  |

| At 30th April 2025 | 1,314 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 30.4.26 |  | 30.4.25

£ | £ |

| Trade debtors | 515 |  | 1,815 |  |

| Directors' current accounts | 6,956 |  | - |  |

7,471 |  | 1,815 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 30.4.26 |  | 30.4.25

£ | £ |

| Corporation tax payable | 15,553 |  | 16,793 |  |

| Directors' current accounts | - |  | 234 |  |

| Accrued expenses | 1,079 |  | 899 |  |

16,632 |  | 17,926 |  |

Bespoke Narcosis Limited (Registered number: 10741984)

Notes to the Financial Statements - continued

for the Year Ended 30th April 2026

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 30.4.26 |  | 30.4.25

| value: | £ | £ |

| 100 | Ordinary A | £1 | 100 |  | 100 |  |

| 3 | Ordinary B | £1 | 3 |  | 3 |  |

| 2 | Ordinary C | £1 | 2 |  | 2 |  |

| 4 | Ordinary D | £1 | 4 |  | 1 |  |

109 |  | 106 |  |

| The Ordinary A shares confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

| The Ordinary B. Ordinary C and Ordinary D shares do not confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

| On 2nd October 2025, 3 Ordinary D shares each of £1 were allotted, called up and fully paid at par.

8. | DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

| The following advances and credits to a director subsisted during the years ended 30th April 2026 and 30th April 2025:

| 30.4.26 |  | 30.4.25

£ | £ |

| Dr D R Nethercott

| Balance outstanding at start of year | (235 | ) | (573 | ) |

| Amounts advanced | 60,317 |  | 65,666 |  |

| Amounts repaid | (53,126 | ) | (65,328 | ) |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | 6,956 |  | (235 | ) |

| The loan is repayable on demand and no interest was charged during the year.

9. | CONTROL

| The ultimate controlling party is Dr D Nethercott by virtue of holding 100% of the voting share capital.